1. Home
  2. ANNX vs FPH Comparison

ANNX vs FPH Comparison

Compare ANNX & FPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANNX
  • FPH
  • Stock Information
  • Founded
  • ANNX 2011
  • FPH 2009
  • Country
  • ANNX United States
  • FPH United States
  • Employees
  • ANNX N/A
  • FPH N/A
  • Industry
  • ANNX Biotechnology: Pharmaceutical Preparations
  • FPH Real Estate
  • Sector
  • ANNX Health Care
  • FPH Finance
  • Exchange
  • ANNX Nasdaq
  • FPH Nasdaq
  • Market Cap
  • ANNX 362.4M
  • FPH 338.2M
  • IPO Year
  • ANNX 2020
  • FPH 2017
  • Fundamental
  • Price
  • ANNX $1.46
  • FPH $4.95
  • Analyst Decision
  • ANNX Strong Buy
  • FPH
  • Analyst Count
  • ANNX 5
  • FPH 0
  • Target Price
  • ANNX $18.67
  • FPH N/A
  • AVG Volume (30 Days)
  • ANNX 2.2M
  • FPH 155.4K
  • Earning Date
  • ANNX 05-12-2025
  • FPH 04-24-2025
  • Dividend Yield
  • ANNX N/A
  • FPH N/A
  • EPS Growth
  • ANNX N/A
  • FPH 25.45
  • EPS
  • ANNX N/A
  • FPH 0.96
  • Revenue
  • ANNX N/A
  • FPH $237,926,000.00
  • Revenue This Year
  • ANNX N/A
  • FPH N/A
  • Revenue Next Year
  • ANNX N/A
  • FPH N/A
  • P/E Ratio
  • ANNX N/A
  • FPH $5.16
  • Revenue Growth
  • ANNX N/A
  • FPH 12.37
  • 52 Week Low
  • ANNX $1.29
  • FPH $2.83
  • 52 Week High
  • ANNX $7.85
  • FPH $6.71
  • Technical
  • Relative Strength Index (RSI)
  • ANNX 30.77
  • FPH 44.93
  • Support Level
  • ANNX $1.40
  • FPH $4.61
  • Resistance Level
  • ANNX $1.68
  • FPH $5.15
  • Average True Range (ATR)
  • ANNX 0.18
  • FPH 0.27
  • MACD
  • ANNX 0.00
  • FPH -0.01
  • Stochastic Oscillator
  • ANNX 19.13
  • FPH 41.16

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

About FPH Five Point Holdings LLC

Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational, and recreational elements, as well as civic areas, parks, and open spaces. Its three reportable segments are Valencia, San Francisco, and Great Park. It derives the majority of revenue from the Great Park segment which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.

Share on Social Networks: